Clinical study on the treatment of influenza and upper respiratory tract infection (febrile virus attack lung syndrome) with Qingfeidayuan granules

Hubei Provincial Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Meet the clinical diagnostic criteria for influenza or the diagnostic criteria for acute upper respiratory tract infection;
•2. Comply with the standard of TCM heat-toxin attacking the lung syndrome;
•3. Aged 18-70 years;
•4. Fever duration <=48h; axillary temperature >=37.3?;
•5. The informed consent process complies with the regulations, and the informed consent form is signed.

•1. Severe or critical cases of influenza, or diagnosed as novel coronavirus pneumonia, pharyngeal conjunctival fever, herpetic angina, suppurative tonsillitis, etc.;
•2. Complications of influenza such as sinusitis, otitis media and pneumonia have occurred;
•3. The anti-influenza virus drugs included in the ''Influenza Diagnosis and Treatment Program (2020 Edition)'' have been used within 48 hours before the visit;
•4. Systemically receiving steroid therapy or other immunosuppressive therapy;
•5. Have a history of epilepsy or febrile convulsions;
•6. Patients with severe malnutrition, rickets and serious primary diseases of the heart, brain, liver, kidney and hematopoietic system;
•7. Pregnant or breastfeeding patients, allergic constitution, allergic to multiple drugs or allergic to known components of the research drug;
•8. According to the judgment of the investigator, other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as unstable living environment, inconvenient transportation, etc., are likely to cause loss to follow-up.

发起方